The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | An update on the EMN19 study: Dara-VCd in multiple myeloma
Meral Beksac, MD, PhD, Ankara University, Ankara, Turkey, gives an update on the EMN19 study (NCT04166565), investigating the efficacy of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone (Dara-VCd) in multiple myeloma (MM). The study found high complete response (CR) rates, even in patients with high-risk extramedullary disease. There were also unexpected findings with regard to circulating tumor cells. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: BMS, Takeda, Amgen; Advisory Board: Pfizer, Menarini, Janssen; Speakers Bureau: Janssen.
